Summary
Pfizer Inc. reported strong financial performance for the second quarter and the first six months of 1999, driven by significant growth in total revenues, up 14% and 21% respectively compared to the prior year. This growth was primarily fueled by the Pharmaceutical segment, which saw a 16% increase in Q2 and 24% in H1, with notable contributions from alliance revenues and the launch of Celebrex. Net income also saw a healthy increase of 13% for the quarter and 15% for the half-year. The company's balance sheet reflects a robust increase in total assets and a strategic shift towards higher short-term investments, funded in part by increased short-term borrowings. Looking ahead, Pfizer expressed confidence in meeting analyst expectations for full-year diluted earnings per share, projecting a 20-25% growth rate. The company also provided an update on its Year 2000 compliance efforts, estimating total costs of $140 million and confidence in mitigating potential disruptions through comprehensive business continuity plans. While legal proceedings and environmental matters are ongoing, the company believes they will not have a material adverse effect on its financial position or results of operations.
Key Highlights
- 1Total revenues increased by 14% in Q2 1999 to $3.78 billion and by 21% in H1 1999 to $7.71 billion, driven by strong pharmaceutical sales and alliance revenues.
- 2Net income grew by 13% in Q2 1999 to $709 million and by 15% in H1 1999 to $1.52 billion, demonstrating robust profitability.
- 3Pharmaceutical segment revenue increased significantly, with worldwide sales up 16% in Q2 and 24% in H1, boosted by new product launches like Celebrex and strong performance of key drugs such as Norvasc and Zoloft.
- 4Alliance revenue surged by 143% in Q2 and 154% in H1, primarily due to the co-promotion of Lipitor, Aricept, and the newly launched Celebrex.
- 5The company repurchased approximately 15.2 million shares of common stock in Q2 1999 for about $1.8 billion year-to-date, indicating a commitment to shareholder returns.
- 6Research and Development expenses increased by 21% in Q2 and 28% in H1, reflecting continued investment in drug discovery and development.
- 7The company is actively managing its Year 2000 compliance efforts, with an estimated cost of $140 million and contingency plans in place to minimize potential operational disruptions.